240 related articles for article (PubMed ID: 29986511)
1. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
[TBL] [Abstract][Full Text] [Related]
2. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
Roither B; Oostenbrink C; Schreiner W
BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
Liu W; Huang B; Kuang Y; Liu G
Mol Biosyst; 2017 May; 13(5):892-900. PubMed ID: 28327740
[TBL] [Abstract][Full Text] [Related]
5. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization.
Guo Y; Jin Y; Wang B; Liu B
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946261
[TBL] [Abstract][Full Text] [Related]
8. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
9. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
10. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
12. Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics.
Wu X; Wang N; Liang J; Wang B; Jin Y; Liu B; Yang Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674929
[TBL] [Abstract][Full Text] [Related]
13. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
14. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
[TBL] [Abstract][Full Text] [Related]
15. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
16. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics.
Klyukin K; Alexandrov V
Proteins; 2020 Sep; 88(9):1162-1168. PubMed ID: 32105362
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.
Guo Y; Liang J; Liu B; Jin Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681584
[TBL] [Abstract][Full Text] [Related]
20. Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling.
Carter R; Alanazi F; Sharp A; Roman J; Luchini A; Liotta L; Paige M; Brown AM; Haymond A
J Biol Chem; 2023 Dec; 299(12):105353. PubMed ID: 37858677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
